Skip to main content

statswork

Facebook X-twitter Youtube Linkedin Instagram
Transcripition | Corporate Statistics  | Hire a Statiscian
STATSWORK LOGO
Facebook X-twitter Youtube Linkedin Instagram
STATSWORK LOGO

Meta-Analysis for CROs: Enhance Clinical Strategy With High-Quality Evidence Synthesis

Transcription and Open-Ended Coding

News & Trends

Recommended Reads

Contact us

Meta-Analysis for CROs: Enhance Clinical Strategy With High-Quality Evidence Synthesis

Introduction

Contract Research Organizations (CROs) are an important part of the pharmaceutical company with respect to pharmaceutical drug development. In an increasingly complex clinical trial development and regulatory constraints environment, high-quality and evidence-based strategies have never been as important as they are now. One of the strategies that CROs can take advantage of about enhancing their clinical strategy is using meta-analysis. Meta-analysis is aggregating the data from multiple studies to reach robust, statistically meaningful conclusions and provides a more holistic understanding of treatment effect.[1]

This article will look at how CROs can utilize meta-analysis to streamline trial design, enhance patient and community recruitment, provide a development framework for regulatory submission, and occur faster drug development timeframes.

The Need for High-Quality Evidence Synthesis by CROs

In the ever-increasing competitive environment of the pharmaceutical industry, CROs have the challenge of providing data that is both reliable and actionable. To respond to the ever-increasing demands of regulatory bodies and stakeholders, CROs must provide:

Figure 1 Best Evidence Synthesis Guidelines outlining criteria for evaluating study quality, consistency, and quantity to ensure reliable, reproducible results in clinical trials

Figure 1: Best Evidence Synthesis Guidelines outlining criteria for evaluating study quality, consistency, and quantity to ensure reliable, reproducible results in clinical trials.

  • Reliable and Reproducible Results: Consistency and statistical significance in clinical trial results.
  • Optimized Trial Design: Effective trial design that meets regulatory guidelines and real-world clinical needs.[2]
  • Proven Risk Mitigation: Identification and minimization of risks while supporting clinical development.
  • Applicable Benefit-Risk Assessment: Evidence of both safety and efficacy-a requirement of regulators and decision-makers when assessing new treatments.

Barriers within Clinical Trials and Common Evidence Gaps

Even with the expertise of CROs, there are still challenges that exist with clinical trials:

  • Variability Between Studies: Study outcomes, patient populations, and endpoints will be highly variable, and researchers may end up with inconsistent conclusions regarding the treatment.
  • Small Sample Size: Many clinical trials have insufficient sample sizes, which lead to decreased power, and missed effects, (especially when looking at rarer events or subgroups).[3]
  • Limited Subgroup Analysis: Lack of subgroup analysis in specific populations (age, comorbidity, ethnicity, etc.), can lead to missed information on how a treatment may perform in those specific populations.
  • Inconsistent Safety and Efficacy Data:Incomplete integration of safety and efficacy data between studies can lead to safety and efficacy gaps in understanding how a drug will have an overall effect.
Meta-analysis for CROs

FIG 2: Clinical Trial Costs by Phase and Therapeutic Area
This figure shows the variation in trial costs across phases and therapeutic areas, reflecting challenges like study variability and small sample sizes.

How Meta-Analysis Supports Clinical Strategy For CROs

Meta-Analysis Benefit Definition % Benefit
Statistical Power and Precision The advantage of combining data is the increased sample size, which gives greater accuracy and reduces the chance of false results. 30%
Improved Precision and Confidence Pooling data improves statistical confidence and minimizes the risk of false positives/negatives. 25%
Identifying Small Effects Enables detection of small treatment effects that may not be significant in individual trials. 20%
Subgroup Analysis Allows analysis of subgroups (e.g., age, comorbidities) to derive treatment relevance. 15%
Personalized Medicine Approach May improve treatment targeting for specific patient populations. [2] 10%
Safety Assessment Pools adverse events to identify rare or long-term safety risks. 10%
Evaluating Durability of Treatment Effects Assesses how long treatment effects are maintained over time. 5%
Benefit–Risk Profile Compares efficacy versus safety to support benefit–risk decision-making. 15%
Positioning a New Treatment Purpose Compares new treatments with existing therapies to support approval decisions. 5%

Table 1: shows you that meta-analysis boosts clinical strategies by enhancing statistical power, precision, safety, and the benefit-risk profile.

How Meta-Analysis Speeds up Drug Development and Regulatory Review

Improving Trial Design

  • Most Effective Study Designs: Identifies potential study designs that were effective in past completed studies to inform patient recruitment and application solely to studies most likely to succeed.[4]
  • Informed Endpoints: Introduces knowledge of endpoints likely to demonstrate treatment effect if measured.
  • Loss of Time to Market
  • Efficient Merge of Evidence: Potentially combine evidence early to allow faster review by regulators, without the need to conduct any additional studies or re-submit data to regulatory agencies.
  • Anticipation of Regulatory Questions: Pro-actively address issues that regulators may be concerned about, to make the approval process shorter.[5]
  • Confidence of Investors and Stakeholders
  • Removes Guesswork: Not only does the use of information lead to confidence, but reliance on evidence is also essential for funding effective clinical research.
  • Repurposed Reputation: Codifying robust evidence consistently is beneficial to replace and rebuild the CRO reputation for new clients. [3]

Best Practices for Conducting Meta-Analysis

  • Start Early: Scan for past evidence as it may affect the design of trials and overall study strategy.
  • Team with Experts: Collaborate with biostatistics or epidemiologists in generating reliable estimates.
  • Documentation in Great Detail: Mapping your evidence process in a transparent manner.
  • Keep It Up to Date: Resolve evidence to indicate the potential liability of relevant evidence to inform new information.

Conclusion

For a Contract Research Organization (CRO), the meta-analysis can be an important method that can significantly increase a clinical strategy. Meta-analysis can increase statistical power by combining information in many studies, detail subgroup analyses, improve safety, and enhance the benefit-risk assessment of treatments.[5] For a CRO, the addition of meta-analysis into clinical trials and regulatory submissions will advance the speed of drug development and further strengthen the case for approval. Embracing a foundation based on evidence allows for better risk management, improved clinical strategy, and the development of richer, more meaningful, and actionable insights and advice for pharmaceutical companies while speeding the rate to market for new therapies.

Boost your clinical strategy with data-driven insights.
At Statswork, we specialize in meta-analysis services that help CROs and pharmaceutical companies achieve faster, more reliable results. Contact us today to learn more!

References

  1. Wang XM, Zhang XR, Li ZH, Zhong WF, Yang P, Mao C. A brief introduction of meta-analyses in clinical practice and research. J Gene Med. 2021;23(5):e3312. doi:10.1002/jgm.3312https://pmc.ncbi.nlm.nih.gov/articles/PMC8243934/
  2. Droitcour, J., Silberman, G., & Chelimsky, E. (1993). Cross-design synthesis: a new form of meta-analysis for combining results from randomized clinical trials and medical-practice databases. International Journal of Technology Assessment in Health Care, 9(3), 440-449.https://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care/article/abs/crossdesign-synthesis-a-new-form-of-metaanalysis-for-combining-results-from-randomized-clinical-trials-and-medicalpractice-databases/F00DA55BF442840DF5AD36CFBC1B1D01
  3. Watkins, L., Ledbetter-Cho, K., O’Reilly, M., Barnard-Brak, L., & Garcia-Grau, P. (2019). Interventions for students with autism in inclusive settings: A best-evidence synthesis and meta-analysis. Psychological bulletin, 145(5), 490.https://psycnet.apa.org/buy/2019-12807-001
  4. Hu, F., Jiang, C., Shen, J., Tang, P., & Wang, Y. (2012). Preoperative predictors for mortality following hip fracture surgery: a systematic review and meta-analysis. Injury, 43(6), 676-685.https://www.sciencedirect.com/science/article/abs/pii/S0020138311002117
  5. Cross, A. J., Buchbinder, R., Mathieson, S., Bourne, A., Maher, C. G., Lin, C. W. C., & O’Connor, D. A. (2022). Barriers and enablers to monitoring and deprescribing opioid analgesics for chronic non-cancer pain: a systematic review with qualitative evidence synthesis using the Theoretical Domains Framework. BMJ Quality & Safety, 31(5), 387-400.https://qualitysafety.bmj.com/content/31/5/387.abstract

Contact us